Deuteration of Drugs for Pharmacokintic Enhancement: Considerations Essential for Success
|
|
- Bruno Williamson
- 5 years ago
- Views:
Transcription
1 Deuteration of Drugs for Pharmacokintic Enhancement: Considerations Essential for Success Alvin D.. Vaz Alfin D. Vaz Pfizer Global Research and Development Groton, CT, USA Collaborators: Raman Sharma, Tim Strelevitz, Aarti Sawant, Alan Clark, Elaine Tseng, Hongying Gao, Klass Schildnegt, Patrick Verhoest, Vinod Parikh,
2 Uses for Deuterated Drugs As an internal standard in quantitative analysis Three or more non-exchangeable deuterium atoms incorporated to mass-differentiate the internal standard and analyte Alter pharmacokinetic or toxic properties Deuterium substitution for hydrogen does not appreciably change physicochemical properties such as polar surface area, molecular volume, hydrogen bonding, is naturally abundant to 0.09%, 09% and is OT radioactive. One or more deuterium atoms substituted t at specific sites can slow metabolic clearance and result in: Increases in C max, drug exposure (AUC), and systemic half- life (T 1/2 ) Decreased metabolically generated toxic metabolites
3 Origin of the Kinetic Deuterium Isotope Effect (KDIE) Difference in mass between deuterium and hydrogen results in a zero-point energy difference between C-H and C-D bonds, consequently an increase in energy required to break a C-D bond If the transition state involves a symmetrical breaking of a C-H bond, substitution of hydrogen by deuterium slows down the reaction rate by a factor of 5 9 KDIE = k H /k D ~ 5 _ 9 Enzyme intrinsic isotope effect = D k 1 / H k 1 The intrinsic isotope effect reflects the enzyme s commitment to catalysis In pharmacokinetics the intrinsic clearance isotope effect reflects the In pharmacokinetics the intrinsic clearance isotope effect reflects the kinetic isotope effect on the first order rate constant for disappearance of substrate or V max /K m
4 Press releases by Concert Pharmaceuticals 43% increase in preclinical (monkey) half life (4.5 to 6.3 hrs) for deuterated Linezolid Oct 27th 2008 Phase 1 start for deuterated Paroxetine Sept. 25th, 2008; announced protection against CYP2D6 inactivation Sept. 29th, 2009 Phase 1b multiple dose escalation study for deuterated Atazanavir ov 9th, 2009 Expectation: QD dosing without Ritonavir co-administration Effect of deuterium substitution on sympathomimetic amines on adrenergic responses. Belleau, B.; Burba, J.; Pindell, M.; Reiffenstein, J. Science (1961),
5 Systemic Clearance Mechanism and KDIEs on Pharmacokinetics CL systemic = CL H + CL extrahepatic CL urine + CL other Clearance enzymes where KDIEs apply Aldehyde Oxidase 4 6 Monoamine Oxidases 2 9 Cytochromes P Alcohol/aldehyde CL metabolic + CL bile Clearance enzymes where KDIEs do not apply Flavin monooxygenases Glucuronyl transferases Sulfotransferases Glutathione-S-transferases dehydrogenases 6 8 -acetyl trasferases For pharmacokinetic enhancement: Metabolic clearance must determine systemic clearance The enzyme(s) involved must have KDIEs on their intrinisic clearance
6 Why KDIEs with aldehyde oxidase? Aldehyde Oxidase (AO) is a cytosolic molybdopterin class oxidase, hydroxylates nitrogen heterocycles to the nitrogen Experience with human PK failure due to high clearance by AO Interspecies variability that results in failure of allometric scaling Lack of direct in vitro to in vivo correlation in clearance scaling possibly due to wide tissue distribution Proposed reaction mechanism involves a rate-limiting hydride/proton abstraction Potential to alter PK by use of KDIE
7 KDIEs to establish interspecies commonality in the AO reaction mechanism Intra-molecular isotope effect (intrinsic) H H Spectra of hydroxylated y metabolite of pthalazine after 30 minute incubation in guinea k H pig/ human cytosol D H k D OH D 90 H 1-2 H-Phthalazine 80 5:1 ratio D/H H O 70 H m/z 148 D H 60 O Intensity m/z 147 OH H m/z H D k H k D 2-2 H-Quinoxaline O H M+H amu k H /k D = m/z148 / m/z147 M+H = 147 amu M+H amu D k H /k D = m/z148 / m/z147 H O M+H = 147 amu Substrate H k / D k with cytosolic AO from Guinea pig Rat human 2-2 H-Quinoxaline H-Phthalazine
8 Inter-molecular KDIE on competitive first order elimination rate constants Substrate H k / D k with cytosolic AO from human rat guinea pig Quinoline Carbazeran Zoniporide
9 Inter-molecular KDIE on steady state kinetic constants v/s inolone l/min/ml 2-qu pmol Vmax 5: Quinoline [um] Quinoline 2-2 H-Quinoline K m (mm) V max (pmol/min) V max / K m KDIE on Cl int = 6.0
10 Conclusions from in-vitro KDIEs for AO- catalyzed reactions Across species the rate-limiting step in AO-catalyzed reactions is proton/hydride abstraction The KDIE for AO is fully expressed on the intrinsic clearance (V max /K m ) If systemic clearance of a drug is metabolically driven by AO, pharmacokinetics could be altered
11 Theoretical relationship between clearance (CL) and intrinsic clearance (CL int) ) for a KDIE of 7.0 CL = Q x CL int If CL int >> Q; CL ~ = Q Q + CL int Blood flow limit (Q) proto- deutero- Systemic half-life not expected to change for an IV or orally dosed drug. AUC and C max may reflect the KDIE on the extra-hepatic contributions to overall clearance CL If CL int << Q; CL = ~ Cl int Systemic half-life, AUC and C max may reflect the KDIE on the Cl int -0.3 CL int /Q
12 Pfizer drugs examined in-vitro and in-vivo Aldehyde Oxidase component to metabolism Monoamine Oxidase component to metabolism
13 Intrinsic clearance KDIE for Carbazeran Substrate Human Rat Guinea Pig Cytosol Hepatocytes Cytosol Hepatocytes Cytosol S-9 Carbazeran Metabolite profile for carbazeran 100 Intensity Glucuronide m/z Carbazeran m/z Hydroxy Carbazeran m/z 377 Human Hepatocytes Human S9 + cofactors Intensity Guinea Pig S9 + cofactors Inten nsity Rat Hepatocytes Rat S9 + cofactors Time (min)
14 Prediction of Carbazeran pharmacokinetic outcome from in-vitro assays In human: o PK enhancement In guinea pig and rat: o effect on systemic half-life (blood flow limited clearance ) Possible increases in Cmax and AUC due to KDIE on intrinsic i i clearance (extrahepatic AO contribution)
15 KDIE on PK parameters for Carbazeran (Guinea pigs) KDIE (D/H) AUC T1/2 Mean Std. Dev (Guinea pigs) KDIE (D/H) AUC T1/2 Cmax Mean Std. Dev IV-dosed Orally-dosed (Rats) KDIE (D/H) AUC T1/2 Mean Std. Dev (Rats) KDIE (D/H) AUC T1/2 Cmax Mean Std. Dev Despite a common metabolic pathway, the guinea pig and rat differ in the outcome of KDIEs on the pharmacokinetic parameters, suggesting a species difference in their systemic clearance mechanisms
16 Intrinsic clearance KDIE for Zoniporide Substrate Human Rat Guinea Pig Cytosol Hepatocytes Cytosol Hepatocytes Cytosol S-9 supplemented Zoniporide RT: Intensity uau Metabolite profile for Zoniporide in rat hepatocytes M1 M M2 M M M5 M7 M8 M M L: 5.07E8 TIC F: + c ESI Full ms [ ] MS data L: 1.57E5 nm= PDA data Time (min) zoniporide
17 (Guinea pig) KDIE (D/H) AUC T1/2 Mean Std. Dev (Guinea pig) KDIE (D/H) AUC T1/2 Cmax KDIE on PK parameters for Zoniporide IV-dosed Orally-dosed (Rat) KDIE (D/H) AUC T1/2 Mean Std. Dev (Rat) KDIE (D/H) AUC T1/2 Cmax Mean Mean Std. Dev Std. Dev As predicted from in-vitro hepatoctyes experiments, essentially no effect is observed on the pharmacokinetics of Zoniporide in guinea pig and rat
18 KDIEs on the steady-state kinetic parameters for oxidation of parasubstituted phenethylamines by Monoamine Oxidase -A proteo deutero isotope effects kcat Km kcat Km D kcat D (kcat/km) substituent (min-1) ( M) (min-1) ( M) D CL int H OH CF F Cl Br Me O Taken from: andigama and Edmondson, Biochemistry (2000), 39(49),
19 Proposed Mechanism of MAO-catalyzed deaminations
20 Properties and clinical results for CP P lasma Concent tration (ng/ml) of (1) (D 2 )H 2 C H CP O O 10 mg 30mg 100mg 300mg 1000mg Time (hr) Known attributes: MAO-A substrate Un-desirable clinical PK characterized by Clp/F> 200mL/min/kg; Plasma elimination t 1/2 : ~ 8.5 h Large variability in PK on-linear PK ast(ng*hr/m ml) (ng*h/ml L) AUC0-tl AUC Dose (mg)
21 Low contribution of MAO to CP clearance in the rat Intrinsic clearance KDIE for CP System H k/ D k Microsomes - ADPH 2.5 Microsomes + ADPH 1.1 Hepatocytes 1.1 Radiolabel Disposition of CP in Rat Metabolites Urine (U) Feces (F) U+F M1A 0.06 D 0.06 M M1B M M2A 0.08 D 0.08 M4 (MAOpathway) M (unchanged drug) Total Conclusion from in-vitro KDIE o effect on PK Solubility: > 5 mg/ml; Caco 2 : Papp AB : 1.2x 10-6 ; Papp: BA/AB: 7
22 IV and oral pharmacokinetic isotope effect for CP in the rat 1000 Mean 100 IV CP PF Oral CP PF Conc ( n g /m L ) 10 centration (ng/ml) Plasma Conc Time (hrs) Time (h) KDIE (IV) Rat# AUC T1/2 Mean Std. Dev
23 KDIE in human in vitro systems for CP System H k/ D k Human Microsomes - ADPH 4.3 Microsomes + ADPH 3.8 Hepatocytes 5.7 rmao-a A Large KDIE in human in vitro systems suggest possible PK enhacement The presence of other clearance routes (biliary/absorption) may not favor overall enhancement of pharmacokinetic parameters
24 Sandwich cultured hepatocyte billiary excretion model (1) in BD109 Rosuvastatin in BD pmol/mg protein Ca -Ca pmol/mg protein Ca+ Ca Time(min) i Time Uptake, app Cl b BEI (%) (pmol/min/ (ul/min/mg mg) protein) Rosuvastatin CP
25 Studies with PF-X KDIE in rat and human in vitro systems In Development 5X higher clearance at FIH than predicted MAO contributes tes to metabolism Known metabolic pathways System H k/ D k rmao-a 2.8 RLM + ADPH 1.09 Rat hepatocytes 1.06 Human hepatocytes 1.4 O X H R (D 2 )H 2 Ph H R (D 2 )H 2 CYP Ph O X O MAO-A OH O HO Ph O X Conclusion: o KDIE on the intrinsic clearance in rat hepatocytes and a small KDIE in human hepatocytes suggests deuteration will not enhance pharmacokinetics in either rat or humans
26 Rat IV and oral PK profiles for PF-X Conc (ng/ml) PF IV PF Time (hrs) Plasma Con nc. of PF (ng/ml L) Mean 1000 Oral PF PF Time (hrs) Essentially no KDIE on IV or oral PK parameters for PF-X
27 Considerations for deuteration as a PK enhancement strategy The identity of enzymes involved in the metabolic clearance Knowledge of their reaction mechanisms The extent of their contribution to the overall metabolic clearance Magnitude of the intrinsic i i clearance isotope effect tin hepatocytes (or equivalent) for multiple species Knowledge of other non-metabolic clearance mechanisms and the extent of their contribution to systemic clearance
Chapter 4. Drug Biotransformation
Chapter 4 Drug Biotransformation Drug Biotransformation 1 Why is drug biotransformation necessary 2 The role of biotransformation in drug disposition 3 Where do drug biotransformation occur 4 The enzymes
More informationDeuterium Isotope Effects on Drug Pharmacokinetics I: System-Dependent Effects of Specific Deuteration with Aldehyde Oxidase Cleared Drugs.
DMD Fast This Forward. article has not Published been copyedited on and December formatted. The 21, final 2011 version as may doi:10.1124/dmd.111.042770 differ from this version. DMD#42770 1 Title Page
More informationUsing Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop
Using Accelerator Mass Spectrometry to Explain the Pharmacokinetics of Vismodegib Cornelis E.C.A. Hop Topics to be Addressed Why AMS? AMS for mass balance studies with vismodegib AMS for absolute bioavailability
More informationBasic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester
Basic Concepts in Pharmacokinetics Leon Aarons Manchester Pharmacy School University of Manchester Objectives 1. Define pharmacokinetics 2. Describe absorption 3. Describe distribution 4. Describe elimination
More informationB. Incorrect! Compounds are made more polar, to increase their excretion.
Pharmacology - Problem Drill 04: Biotransformation Question No. 1 of 10 Instructions: (1) Read the problem and answer choices carefully, (2) Work the problems on paper as 1. What is biotransformation?
More informationMODULE No.26: Drug Metabolism
SUBJECT Paper No. and Title Module No. and Title Module Tag PAPER No. 9: Drugs of Abuse MODULE No. 26: Drug Metabolism FSC_P9_M26 TABLE OF CONTENTS 1. Learning Outcomes 2. Introduction 3. Sites of Drug
More informationINTRODUCTION TO PHARMACOKINETICS
INTRODUCTION TO PHARMACOKINETICS 1 http://www.biology.iupui.edu/biocourses/biol540/4pipeline2css.html 2 PHARMACOKINETICS 1. ABSORPTION 2. DISTRIBUTION 3. METABOLISM 4. EXCRETION ALL THESE PROCESSES ARE
More informationNON-P450-MEDIATED METABOLISM: IDENTIFICATION AND IMPLICATION DURING COMPOUND SELECTION AND OPTIMIZATION
2017 anjing International Conference of Drug Metabolism -P450-MEDIATED METABLISM: IDETIICATI AD IMPLICATI DURIG CMPUD SELECTI AD PTIMIZATI Xiaoliang Zhuo Metabolism and Pharmacokinetics Preclinical Candidate
More informationMEDCHEM 570. First Midterm. January 30, 2015
Name MEDCHEM 570 First Midterm January 30, 2015 Instructions: Exam packet totals 7 pages. The last page has a 5 points extra credit question. If you need additional space for a question go to the back
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More informationSection 5.2: Pharmacokinetic properties
Section 5.2: Pharmacokinetic properties SmPC training presentation Note: for full information refer to the European Commission s Guideline on summary of product characteristics (SmPC) SmPC Advisory Group
More informationMetabolism. Objectives. Metabolism. 26 July Chapter 28 1
Metabolism bjectives Describe various processes by which drugs are metabolized Describe induction and inhibition of metabolism Use the venous equilibration model to describe hepatic clearance and the effect
More informationClick to edit Master title style
A Short Course in Pharmacokinetics Chris Town Research Pharmacokinetics Outline Pharmacokinetics - Definition Ideal Pharmacokinetic Parameters of a New Drug How do we optimize PK for new compounds Why
More informationToxicant Disposition and Metabolism. Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine
Toxicant Disposition and Metabolism Jan Chambers Center for Environmental Health Sciences College of Veterinary Medicine chambers@cvm.msstate.edu Definitions Disposition Absorption passage across membrane.
More informationMETABOLISM. Ali Alhoshani, B.Pharm, Ph.D. Office: 2B 84
METABOLISM Ali Alhoshani, B.Pharm, Ph.D. ahoshani@ksu.edu.sa Office: 2B 84 Metabolism By the end of this lecture, you should: Recognize the importance of biotransformation Know the different sites for
More informationAssessing the role of hepatic uptake in drug clearance - Pharmacokinetic and experimental considerations
Assessing the role of hepatic uptake in drug clearance - Pharmacokinetic and experimental considerations Peter Webborn ISSX Short course Toronto 2013 1 Defining the why, when and how of Transporter studies
More informationCulture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug Interaction. Chuang Lu
Culture Hepatocytes in Human Plasma to Count the free Concentration of Drug in Evaluation of Drug-drug nteraction Chuang Lu Millennium, The Takeda Oncology Company Cambridge, MA, USA DD 205, Seattle, 6/29/205
More informationThe Analysis of Isotopically Labeled Propylene Glycol in ecigarettes
The Analysis of Isotopically Labeled Propylene Glycol in ecigarettes Raymond H. Farmen, Ph.D. The Coolest ecigarette Clinical Study Using Isotopically Labeled Propylene Glycol Raymond H. Farmen, Ph.D.
More informationIndustrial Toxicology
Industrial Toxicology Learning Objectives Know the assumptions of the doseresponse and time-course curves Be able to define and label key points of a curve Know the difference between potency and efficacy
More informationBIOPHARMACEUTICS and CLINICAL PHARMACY
11 years papers covered BIOPHARMACEUTICS and CLINICAL PHARMACY IV B.Pharm II Semester, Andhra University Topics: Absorption Distribution Protein binding Metabolism Excretion Bioavailability Drug Interactions
More informationDEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA
METABOLISME dr. Yunita Sari Pane DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA Pharmacokinetic absorption distribution BIOTRANSFORMATION elimination Intravenous Administration Oral
More informationPublic Assessment Report. Scientific discussion. Ropinirol Actavis. Ropinirole hydrochloride DK/H/1212/ /DC
Public Assessment Report Scientific discussion Ropinirol Actavis Ropinirole hydrochloride DK/H/1212/001-007/DC This module reflects the scientific discussion for the approval of Ropinirole film-coated
More informationDMPK. APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology
DMPK APRIL 27 TH 2017 Jan Neelissen Scientific Adviser Science & Technology What I learned is a good DMPK profile have acceptable water solubility for development be completely absorbed, preferably via
More informationXTreme 200 Human Liver Microsomes Lot No Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose
XTreme 200 Human Liver Microsomes Lot No. 1710084 Human Liver Microsomes Pool of 200 (100 Male and 100 Female) Suspension medium: 250 mm sucrose H2610 0.5 ml at 20 mg/ml H2620 1.0 ml at 20 mg/ml H2630
More informationOrientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology
Orientation for New Child and Adolescent Psychiatry Residents: Module Four Pediatric Psychopharmacology Objective: To discuss basic principles of psychopharmacology in children and adolescents. Pharmacokinetics:
More informationBiologic Oxidation BIOMEDICAL IMPORTAN
Biologic Oxidation BIOMEDICAL IMPORTAN Chemically, oxidation is defined as the removal of electrons and reduction as the gain of electrons. Thus, oxidation is always accompanied by reduction of an electron
More informationStrategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population
Strategies for Developing and Validating PBPK Models for Extrapolation to Unstudied Population Nina Isoherranen Department of Pharmaceutics University of Washington Processes driving drug disposition are
More informationBuilding innovative drug discovery alliances. Hepatic uptake and drug disposition o in vitro and in silico approaches
Building innovative drug discovery alliances Hepatic uptake and drug disposition o in vitro and in silico approaches Dr Beth Williamson Evotec AG, 2017 Outline Importance of predicting clearance In vitro
More informationPharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches.
Pharmacokinetic and absolute bioavailability studies in early clinical development using microdose and microtracer approaches. Lloyd Stevens PhD Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationIt the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues.
It the process by which a drug reversibly leaves blood and enter interstitium (extracellular fluid) and/ or cells of tissues. Primarily depends on: 1.Regional blood flow. 2.Capillary permeability. 3.Protein
More informationAldehyde Oxidase and Donor Variability Challenges to Estimating Human Clearance
Aldehyde Oxidase and Donor Variability Challenges to Estimating Human Clearance J. Matthew Hutzler, Ph.D. Quintiles Bioanalytical and ADME Labs Indianapolis, I Copyright 2014 Quintiles Emergence of Aldehyde
More informationIII. TOXICOKINETICS. Studies relevant to the toxicokinetics of inorganic chloramines are severely
III. TOXICOKINETICS Introduction Studies relevant to the toxicokinetics of inorganic chloramines are severely limited. However, studies done with various chlorinated amino compounds (including organic
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development
Biopharmaceutics Drug Disposition Classification System (BDDCS) and Its Application in Drug Discovery and Development Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences University
More information1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?
Page 1 PHAR 750: Biopharmaceutics/Pharmacokinetics October 23, 2009 - Form 1 Name: Total 100 points Please choose the BEST answer of those provided. For numerical answers, choose none of the above if your
More informationHuman ADME Study Design Considerations in Healthy Subjects and in Patients
Human ADME Study Design Considerations in Healthy Subjects and in Patients Daria Stypinski BSc (Pharm), PhD Clinical Pharmacology Sciences Nov 18, 2015 Learning Goals and Outline What is a human ADME study?
More informationThe Opportunity: c-ibs and pain relief with confidence YKP10811
The Opportunity: c-ibs and pain relief with confidence YKP10811 1 TABLE OF CONTENTS Profile Summary Clinical Data Mode of Action Pharmacologic Profile Safety and Toxicity Profile ADME Overview vs. Competitors
More informationExploiting BDDCS and the Role of Transporters
Exploiting BDDCS and the Role of Transporters (Therapeutic benefit of scientific knowledge of biological transporters, understanding the clinical relevant effects of active transport on oral drug absorption)
More informationMetabolic Changes of Drugs and Related Organic Compounds
Metabolic Changes of Drugs and Related Organic Compounds 3 rd stage/ 1 st course Lecture 3 Shokhan J. Hamid 2 Metabolism plays a central role in the elimination of drugs and other foreign compounds from
More informationChapter 9. Biotransformation
Chapter 9 Biotransformation Biotransformation The term biotransformation is the sum of all chemical processes of the body that modify endogenous or exogenous chemicals. Focus areas of toxicokinetics: Biotransformation
More informationT Eley, Y-H Han, S-P Huang, B He, W Li, W Bedford, M Stonier, D Gardiner, K Sims, P Balimane, D Rodrigues, RJ Bertz
IN VIVO AND IN VITRO ASSESSMENT OF ASUNAPREVIR (ASV; BMS-650032) AS AN INHIBITOR AND SUBSTRATE OF ORGANIC ANION TRANSPORT POLYPEPTIDE (OATP) TRANSPORTERS IN HEALTHY VOLUNTEERS T Eley, Y-H Han, S-P Huang,
More informationDRUG METABOLISM AND PHARMACOKINETICS (DMPK) Lena Gustavsson, H. Lundbeck A/S, November 2015
DRUG METABOLISM AND PHARMACOKINETICS (DMPK), H. Lundbeck A/S, LEGU@lundbeck.com November 2015 DMPK in Drug Discovery and Development Agenda Introduction Optimizing pharmacokinetic properties Absorption
More information2. List routes of exposure in the order of most rapid response.
Practice Test questions: 1. What are the two areas of toxicology that a regulatory toxicologist must integrate in order to determine the "safety" of any chemical? 2. List routes of exposure in the order
More informationComplexities of Hepatic Drug Transport: How Do We Sort It All Out?
Complexities of Hepatic Drug Transport: How Do We Sort It All Out? Keith A. Hoffmaster Pfizer Research Technology Center Cambridge, MA NEDMDG 2005 Summer Symposium 06.08.2005 The Challenge Intestinal uptake
More informationRSC, February Interplay between enzymes and. clearance and intracellular concentration of drugs. Centre for Applied Pharmacokinetic Research
RSC, February 2014 Interplay between enzymes and transporters in defining hepatic drug clearance and intracellular concentration of drugs J Brian Houston Centre for Applied Pharmacokinetic Research (CAPkR)
More informationInvolvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338
Involvement of CYP2C8 and UGT1A9 in the metabolism of a novel gastroprokinetic agent, Z-338 S. Furuta 1, E. Kamada 1, T. Sugimoto 1, Y. Kawabata 1, X. C. Wu 2, J. Skibbe 3, E. Usuki 3, A. Parkinson 3 and
More informationInfluence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments
Influence of fluvoxamine on carvedilol metabolism and plasma disposition in vitro and in vivo experiments MARIA BIANCA ABRUDAN* 1, DANA MARIA MUNTEAN 1, DANIELA SAVETA POPA 2, LAURIAN VLASE 1, ANA-MARIA
More informationMetabolic Changes of Drugs and Related Organic Compounds
Metabolic Changes of Drugs and Related Organic Compounds 3 rd stage/ 1 st course Lecture 7 Shokhan J. Hamid 1 Phase II or Conjugation Reactions Phase I or functionalization reactions do not always produce
More informationA novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers
A novel microdose approach to assess bioavailability, intestinal absorption, gut metabolism, and hepatic clearance of simeprevir in healthy volunteers Sivi Ouwerkerk-Mahadevan, 1 Jan Snoeys, 1 Alex Simion,
More informationDrug Metabolism Phase 2 conjugation reactions. Medicinal chemistry 3 rd stage
Drug Metabolism Phase 2 conjugation reactions Medicinal chemistry 3 rd stage 1 Phase II or Conjugation reactions 1. Glucuronic acid conjugation 2. Sulfate conjugation 3. Glycine and Glutamine conjugation
More informationPractical Application of PBPK in Neonates and Infants, Including Case Studies
Practical Application of PBPK in Neonates and Infants, Including Case Studies Presented at the conference : Innovative Approaches to Pediatric Drug Development and Pediatric Medical Countermeasures: A
More informationPharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core
Pharmacokinetics in Drug Development Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core Finding new drugs: A crap shoot Clinical Development Phase
More informationPrinciples of Toxicokinetics/Toxicodynanics
Biochemical and Molecular Toxicology ENVR 442; TOXC 442; BIOC 442 Principles of Toxicokinetics/Toxicodynanics Kim L.R. Brouwer, PharmD, PhD kbrouwer@unc.edu; 919-962-7030 Pharmacokinetics/ Toxicokinetics:
More informationPhase I in clinical drug development
Phase I in clinical drug development M2 Pharmacocinétique 31 janvier 2013 Philippe Grosjean Sanofi R&D Clinical Sciences and Operations 1 New drug investigations in human Objectives of the clinical investigations
More informationBasic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations Rosenbaum, Sara E. ISBN-13: 9780470569061 Table of Contents 1 Introduction to Pharmacokinetics and Pharmacodynamics.
More informationEVALUATION OF DRUG-DRUG INTERACTION POTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSIOLOGICALLY- BASED PHARMACOKINETIC MODEL
Drug metabolism and Pharmacokinetics/PK Sciences EVALUATIN F DRUG-DRUG INTERACTIN PTENTIAL BETWEEN SACUBITRIL/VALSARTAN (LCZ696) AND STATINS USING A PHYSILGICALLY- BASED PHARMACKINETIC MDEL Imad Hanna,
More informationMechanism of Detoxification
Mechanism of Detoxification Prof.Dr. Hedef Dhafir El-Yassin 1 Objectives: 1. To list the detoxification pathways 2. To describe detoxification pathways and phases in the liver, 2 3 4 o Xenobiotics are
More informationBiopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application
Biopharmaceutics Drug Disposition Classification System (BDDCS) --- Its Impact and Application Leslie Z. Benet, Ph.D. Professor of Bioengineering and Therapeutic Sciences Schools of Pharmacy and Medicine
More informationAbsolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches.
Absolute bioavailability and pharmacokinetic studies in early clinical development using microdose and microtracer approaches. Dr Lloyd Stevens Senior Research Fellow Pharmaceutical Profiles Nottingham,
More informationSix Types of Enzyme Catalysts
Six Types of Enzyme Catalysts Although a huge number of reactions occur in living systems, these reactions fall into only half a dozen types. The reactions are: 1. Oxidation and reduction. Enzymes that
More informationWaters ASMS Users Meeting May 30 th, Overview
Application of accurate mass spectrometry to mechanistic studies of metabolismdependent inhibition of cytochrome P45 enzymes Joanna Barbara, Ph.D. XenoTech Waters AM 29 Users Meeting May 3, 29 verview
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationTake-Home Exam Distributed: October 16, 2013, at 1:30 p.m. Due: October 21, 2013, at 10:00 a.m.
20.201 Take-Home Exam Distributed: October 16, 2013, at 1:30 p.m. Due: October 21, 2013, at 10:00 a.m. Directions: This take-home exam is to be completed without help from any other individual except:
More informationLippincott Questions Pharmacology
Lippincott Questions Pharmacology Edition Two: Chapter One: 1.Which one of the following statements is CORRECT? A. Weak bases are absorbed efficiently across the epithelial cells of the stomach. B. Coadministration
More informationAMS: A smarter way to cut through the MIST. Bob Ings RMI-Pharmacokinetics
AMS: A smarter way to cut through the MIST Bob Ings RMI-Pharmacokinetics www.rmi-pharmacokinetics.com Objectives Brief overview of Accelerator Mass Spectrometry (AMS) and its history Reminder of the MIST
More information1. Measurement of the rate constants for simple enzymatic reaction obeying Michaelis- Menten kinetics gave the following results: =3x10-5 = 30μM
1. Measurement of the rate constants for simple enzymatic reaction obeying Michaelis- Menten kinetics gave the following results: k 1 = 2 x 10 8 M -1 s -1, k 2 = 1 x 10 3 s -1, k 3 = 5 x 10 3 s -1 a) What
More informationDr. Nafeth Abu-Tarbou sh Introduction to Biochemist ry 15/08/2014 Sec 1,2, 3 Sheet #21 P a g e 1 Written by Baha Aldeen Alshraideh
P a g e 1 Enzyme Kinetics Vmax: The Maximal rate - The rate of reaction when the enzyme is saturated with substrate. -You can calculate it by the following equation: Vmax = k2 [E] T [E]T :Total enzyme
More informationEdgar Naegele. Abstract
Simultaneous determination of metabolic stability and identification of buspirone metabolites using multiple column fast LC/TOF mass spectrometry Application ote Edgar aegele Abstract A recent trend in
More informationNonlinear Pharmacokinetics
Nonlinear Pharmacokinetics Non linear pharmacokinetics: In some cases, the kinetics of a pharmacokinetic process change from predominantly first order to predominantly zero order with increasing dose or
More informationSylvie Klieber, Catherine Arabeyre-Fabre, Patricia Moliner, Eric Marti, Martine Mandray, Robert Ngo, Celine Ollier, Priscilla Brun & Gerard Fabre
ORIGINAL ARTICLE Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug Sylvie Klieber, Catherine
More informationRenal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion
59-291 Section 1, Lecture 5 Drug Excretion -most drugs are excreted in urine either as unchanged or drug metabolites Renal Function 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular
More informationPursuing the holy grail of predicting and verifying tissue drug concentrations: A proteomics and PET imaging approach
Pursuing the holy grail of predicting and verifying tissue drug concentrations: A proteomics and PET imaging approach Jashvant (Jash) Unadkat Milo Gibaldi Endowed Professor Dept. of Pharmaceutics School
More informationAug 28 th, 2017 Pierre Daublain
Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical Species to Inform Derisking Strategies in Discovery and Early Development Aug 28 th, 2017 Pierre Daublain Outline Problem
More informationChapter 11: Enzyme Catalysis
Chapter 11: Enzyme Catalysis Matching A) high B) deprotonated C) protonated D) least resistance E) motion F) rate-determining G) leaving group H) short peptides I) amino acid J) low K) coenzymes L) concerted
More information3) How many different amino acids are proteogenic in eukaryotic cells? A) 12 B) 20 C) 25 D) 30 E) None of the above
Suggesting questions for Biochemistry 1 and 2 and clinical biochemistry 1) Henderson Hasselbalch Equation shows: A) The relationship between ph and the concentration of an acid and its conjugate base B)
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationBASIC PHARMACOKINETICS
BASIC PHARMACOKINETICS MOHSEN A. HEDAYA CRC Press Taylor & Francis Croup Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business Table of Contents Chapter
More informationClinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline
Clinical Pharmacology of DAA s for HCV: What s New and What s in the Pipeline Anita Mathias, PhD Clinical Pharmacology, Gilead Sciences 14 th Int. Workshop on Clinical Pharmacology of HIV Therapy April
More informationCONTENT. i iv ix. SVKM s NMIMS, School of Pharmacy and Technology Management
CONTENT Chapter No. Title Page No. Abbreviations List of Figures List of Tables 1 Introduction 1 1.1 Practical aspects 4 1.2 Stability-indicating assay method (SIAM) 5 1.3 Regulatory aspects 6 1.4 Techniques
More informationObjectives Making CYP450, Drug Interactions, & Pharmacogenetics Easy
Objectives Making, Drug Interactions, & Pharmacogenetics Easy Anthony J. Busti, MD, PharmD, FNLA, FAHA Describe the differences between phase I and phase II metabolic pathways. Identify the most common
More informationPorphyrins: Chemistry and Biology
Porphyrins: Chemistry and Biology 20.109 Lecture 6 24 February, 2011 Goals Explore some essential roles of heme in biology Appreciate how ature has used the same cofactor to achieve diverse functions Gain
More information10th French-Belgian ABC Meeting Brussels, October, 2012
Finding physiological functions of drug transporters using KO mice, LC-MS and transportomics Piet Borst Koen van de Wetering The Netherlands Cancer Institute 10th French-Belgian ABC Meeting Brussels, 19-20
More information1/3/2011. Chapter 17 Carboxylic Acids and Their Derivatives. Nucleophilic Addition- Elimination at the Acyl Carbon
Introduction The carboxyl group (-CO 2 H) is the parent group of a family of compounds called acyl compounds or carboxylic acid derivatives Chapter 17 Carboxylic Acids and Their Derivatives. Nucleophilic
More informationMS/MS as an LC Detector for the Screening of Drugs and Their Metabolites in Race Horse Urine
Application Note: 346 MS/MS as an LC Detector for the Screening of Drugs and Their Metabolites in Race Horse Urine Gargi Choudhary and Diane Cho, Thermo Fisher Scientific, San Jose, CA Wayne Skinner and
More informationPharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects
Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects Dr. Francisco Abad Santos 16 June 2017 Atypical antipsychotics or second generation antipsychotics
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More informationMargaret A. Daugherty. Announcements! Fall Michaelis Menton Kinetics and Inhibition. Lecture 14: Enzymes & Kinetics III
Lecture 14: Enzymes & Kinetics III Michaelis Menton Kinetics and Inhibition Margaret A. Daugherty Fall 2004 Announcements! Monday 10/11 lecture: starts at 10:15; Taught by Dr. Stephen Everse o ffice our/review
More informationBACKGROUND AND PURPOSE
British Journal of Pharmacology DOI:10.1111/j.1476-5381.010.00913.x www.brjpharmacol.org RESEARCH PAPER Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of
More informationThe ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.
1 MEDCHEM 562 Kent Kunze Lecture 1 Physicochemical Properties and Drug Disposition The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.
More informationnumber Done by Corrected by Doctor
number 18 Done by Mahmoud Harbi Corrected by حسام أبو عوض Doctor Nayef Karadsheh Sources of Reactive Oxygen Species (ROS) 1 P a g e 1- Oxidases: there are some that produce hydrogen peroxide (H₂O₂) 2-
More informationMass Spectrometry Introduction
Mass Spectrometry Introduction Chem 744 Spring 2013 What MS is and is not MS is NOT a spectroscopic method. Molecules are not absorbing EM radiation MS is the generation, separation and characterization
More informationMohammad Alfarra. Faisal Al Nemri. Hala Al Suqi
25 Mohammad Alfarra Faisal Al Nemri Hala Al Suqi Review: - Modes of regulation:- Feed-back regulation is when an enzyme present early in a biochemical pathway is regulated by a late product of the pathway.
More informationMODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL
MODELING MECHANISM BASED INACTIVATION USING PBPK JAN WAHLSTROM DIRECTOR, PRECLINICAL ABSTRACT Quantitative prediction of the magnitude of drug-drug interactions (DDI) is critical to underwriting patient
More informationCYP2D6: mirtazapine 2001/2002/2003
CYP2D6: mirtazapine 2001/2002/200 Cl or = oral clearance,=c ss = steady state concentration, EM = extensive metaboliser, IM = intermediate metaboliser, MR = metabolic ratio, NS = non-significant, PM =
More informationPharmacokinetics. Karim Rafaat
Pharmacokinetics Karim Rafaat Pharmacokinetics The therapeutic effect of a drug is determined by the concentration of drug at the receptor site of action. Even though the concentration of drug that reaches
More informationRational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell
1 Rational Dose Prediction Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland, New Zealand 2 Pharmacology Pharmacology is derived from a Greek word (pharmakon). The Greeks used
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More informationComparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization?
Comparison Between the US FDA, Japan PMDA and EMA In Vitro DDI Guidance: Are we Close to Harmonization? Brian Ogilvie, Ph.D. VP Scientific Consulting XenoTech, LLC bogilvie@xenotechllc.com 14 Jun, 2018
More informationPharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines
Pharmacokinetics of Rifampicin in African Children Evaluation of the new WHO dosing guidelines Paolo Denti, Carmen Gonzalez-Martinez, Jana Winckler, Adrie Bekker, Heather Zar, Gerry Davies, Annelies van
More informationChapter 18 Carboxylic Acids and Their Derivatives. Nucleophilic Addition- Elimination at the Acyl Carbon
Chapter 18 Carboxylic Acids and Their Derivatives. Nucleophilic Addition- Elimination at the Acyl Carbon Introduction The carboxyl group (-CO 2 H) is the parent group of a family of compounds called acyl
More informationf FAD C-4a-hydroperoxy form of FMO enzymes 131 flavin monooxygenases 241
j251 Index a absorption, distribution, metabolism, and excretion (ADME) screening and pharmacokinetics 245 protein binding 244 QSAR approaches 246 in silico approaches 245, 246 space, concept of 233 235
More information